Table 1.
Patient demographics and baseline disease characteristics by severe and/or difficult-to-treat AD subgroup (full analysis set)
| IGA 4 n = 296 |
EASI > 21 n = 603 |
EASI > 38 n = 225 |
Failure or intolerance to prior systemic agentsa n = 121 |
%BSA > 50 n = 360 |
%BSA > 65 n = 214 |
Combined subgroupb n = 48 |
|
|---|---|---|---|---|---|---|---|
| Age, mean ± SD, years | 37.6 ± 14.6 | 36.8 ± 14.3 | 36.5 ± 14.3 | 36.4 ± 13.6 | 36.0 ± 14.2 | 36.2 ± 13.9 | 35.3 ± 12.9 |
| Female, n (%) | 130 (43.9) | 276 (45.8) | 91 (40.4) | 40 (33.1) | 153 (42.5) | 90 (42.1) | 12 (25.0) |
| Race, n (%) | |||||||
| White | 183 (61.8) | 415 (68.8) | 161 (71.6) | 85 (70.2) | 242 (67.2) | 141 (65.9) | 27 (56.3) |
| Black or African American | 18 (6.1) | 26 (4.3) | 10 (4.4) | 1 (0.8) | 14 (3.9) | 10 (4.7) | 1 (2.1) |
| Asian | 86 (29.1) | 145 (24.0) | 49 (21.8) | 31 (25.6) | 96 (26.7) | 56 (26.2) | 17 (35.4) |
| Otherc | 9 (3.0) | 17 (2.8) | 5 (2.2) | 4 (3.3) | 8 (2.2) | 7 (3.3) | 3 (6.2) |
| IGA score, n (%) | |||||||
| 3 (moderate) | 0 (0.0) | 322 (53.4) | 64 (28.4) | 58 (47.9) | 162 (45.0) | 74 (34.6) | 0 (0.0) |
| 4 (severe) | 296 (100) | 281 (46.6) | 161 (71.6) | 63 (52.1) | 198 (55.0) | 140 (65.4) | 48 (100.0) |
| %BSA involvement, mean ± SD | 61.8 ± 22.5 | 57.0 ± 20.9 | 75.8 ± 14.2 | 57.9 ± 22.6 | 71.0 ± 14.0 | 80.4 ± 9.8 | 76.3 ± 13.0 |
| EASI score, mean ± SD | 40.4 ± 12.9 | 35.9 ± 11.8 | 48.8 ± 8.0 | 36.8 ± 13.6 | 41.9 ± 11.3 | 47.2 ± 10.5 | 47.3 ± 10.5 |
| PP-NRS score, mean ± SD | 7.8 ± 1.6 | 7.5 ± 1.6 | 7.9 ± 1.5 | 7.4 ± 1.6 | 7.6 ± 1.6 | 7.7 ± 1.6 | 7.7 ± 1.5d |
| POEM score, mean ± SD | 22.6 ± 4.9 | 21.6 ± 5.2 | 23.0 ± 4.9 | 21.1 ± 5.6 | 22.0 ± 5.2 | 22.4 ± 5.0 | 22.5 ± 5.2 |
| DLQI score, mean ± SD | 17.3 ± 6.4 | 16.0 ± 6.4 | 18.1 ± 6.2 | 16.2 ± 6.1 | 16.6 ± 6.4 | 17.8 ± 6.3 | 17.0 ± 6.0 |
AD atopic dermatitis, DLQI Dermatology Life Quality Index, EASI Eczema Area and Severity Index, IGA Investigator’s Global Assessment, POEM Patient-Oriented Eczema Measure, PP-NRS Peak Pruritus Numerical Rating Scale
aExcluding patients who took only corticosteroids
bThe combined subgroup was defined as patients with baseline IGA 4, and EASI > 21, and %BSA > 50, and failure or intolerance to prior systemic agents (excluding patients who took only corticosteroids)
cAmerican Indian or Alaska Native, multiracial, or race not reported
dn = 47 patients